A new Savills market brief says Denver‑Boulder’s life‑sciences real‑estate fundamentals took a breather in the first quarter of 2026, as deliveries of specialized lab space outpaced tenants ready to sign on the dotted line. Landlords are staring at sizeable chunks of speculative lab product while a choosier tenant pool holds out for fully built, fully serviced space. Even so, the region is not going quiet: selective investment and targeted leasing are still keeping parts of the cluster busy.
According to the Savills report, as covered by Mile High CRE, overall vacancy in the Denver‑Boulder life‑sciences market hit 27.3% in Q1 2026, with direct vacancy jumping to 20.5% from 15.2% a year earlier. Savills characterizes the shift as a “normalization” after several years of rapid expansion, with new deliveries landing just as tenant demand turns more cautious.
Different measures, different headlines
Other data sources tell a slightly different story. CBRE reports Q1 direct vacancy at 12.7% across the Denver‑Boulder market and 18.4% in the Boulder submarket, noting there was no net absorption during the quarter because newly leased space is still waiting on tenant build‑outs. The spread between the Savills and CBRE numbers is a reminder that methodology – including how “vacant” and “available” space are defined – can dramatically change the headline.
Tenants favor move‑in‑ready lab product
Savills, as cited by Mile High CRE, also notes that tenants are increasingly picky, with a clear preference for high‑quality, move‑in‑ready lab suites instead of speculative shells or minimally improved R&D space. That kind of demand gives landlords and developers who can offer plug‑and‑play infrastructure, flexible bench configurations and strong service packages a noticeable leg up.
Deals that buck the trend
Even with vacancy climbing, the market is not frozen. BioMed Realty confirmed that VitriVax has leased roughly 31,465 square feet at Flatiron Park’s 5500 Central as an expansion of its Boulder operations. A prior Business Wire release shows VitriVax also closed about $17.25 million in Series B financing to advance its vaccine platform. Those kinds of anchor transactions highlight that capital and strategic growth plans are still pushing selective leasing, even as plenty of space sits on the sidelines.
Big funding still flowing
What brokers and landlords are watching
Local brokers say the next few quarters will hinge on how quickly already leased but unoccupied space gets built out and occupied, and on whether speculative projects start to slow. CBRE notes that Q1 leasing reached about 85,000 square feet across three deals, with rolling four‑quarter leasing at roughly 282,000 square feet and an active development pipeline of around 221,000 square feet. For landlords and brokers, those trends often matter more than any single vacancy statistic…